Pharmaceuticals New Zealand

New Zealand HPV Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

New Zealand HPV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Gender, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $101.8 Mn Placeholder estimate
Estimate 2025 $110.3 Mn 1% of the global market
Projected 2034 $228.0 Mn 106.7% Adds $117.7 Mn over 9 forecast years
CAGR 2025–2034 8.4% Faster than 52% of 166 Pharmaceuticals markets here
Key players 5
  • New Zealand is 1% of the global market.
  • In APAC, the largest is China at $842.9 Mn.
  • Fastest growing: India at 10.7% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$117.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
HPV Vaccines Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $101.8 Mn — —
2025 (base) $110.3 Mn +$8.6 Mn —
2026 (forecast) $119.6 Mn +$9.3 Mn +8.4%
2027 (forecast) $129.7 Mn +$10.0 Mn +17.5%
2028 (forecast) $140.5 Mn +$10.9 Mn +27.4%
2029 (forecast) $152.3 Mn +$11.8 Mn +38.1%
2030 (forecast) $165.1 Mn +$12.8 Mn +49.7%
2031 (forecast) $179.0 Mn +$13.9 Mn +62.2%
2032 (forecast) $194.1 Mn +$15.0 Mn +75.9%
2033 (forecast) $210.4 Mn +$16.3 Mn +90.6%
2034 (forecast) $228.0 Mn +$17.7 Mn +106.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand HPV Vaccines Market Analysis at a glance
Market size, 2025$110.3 Mn placeholder estimate
Forecast, 2034$228.0 Mn placeholder estimate
Growth (CAGR), 2025–20348.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, gender and end user (see all)
Key playersMerck & Co., Inc., GSK PLC, Serum Institute of India, Xiamen Innovax, Walvax Biotechnology (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand HPV Vaccines Market Analysis Executive Summary

HPV vaccines protect against human papillomavirus types that cause cervical and other cancers and genital warts.

Key segments of the HPV Vaccines market include type (9-Valent, Bivalent and Quadrivalent) and gender (Female and Male).

Bar chart: New Zealand HPV Vaccines market size, 2024–2034, placeholder estimates. $101.8 Mn in 2024, $110.3 Mn in 2025 and $228.0 Mn in 2034, 8.4% CAGR.
New Zealand HPV Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand HPV Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the HPV Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the HPV Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the HPV Vaccines market.

Competitive Landscape for HPV Vaccines Market in New Zealand

The HPV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for HPV Vaccines Market in New Zealand

HPV Vaccines in New Zealand: rules and payment

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for HPV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in HPV Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

HPV Vaccines in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 5th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the HPV Vaccines market in New Zealand?
Placeholder estimate: about $110.3 Mn in 2025, rising to about $228.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the HPV Vaccines market in New Zealand growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the HPV Vaccines market report cover?
The report splits the market by type (9-Valent, Bivalent, Quadrivalent), gender (Female, Male) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the HPV Vaccines market?
Key players include Merck & Co., Inc., GSK PLC, Serum Institute of India, Xiamen Innovax and Walvax Biotechnology.
What is driving the HPV Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the HPV Vaccines market.
Who regulates HPV Vaccines in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How much research is published on HPV Vaccines?
PubMed lists 1,087 papers on HPV Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in New Zealand

See all

Related on vaccines and women's health

See the topic